Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE D46/EVOKE-03: pembrolizumab + sacituzumab govitecan vs pembrolizumab alone in first-line metastatic non-small cell lung cancer with PD-L1 TPS >=50%
MOH_2022-10-26_012146Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + sacituzumab govitecan with Pembrolizumab alone (2 arms). Started Oct 2022; status: active, not recruiting.
02
Drugs
pembrolizumabsacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2022-10-26_012146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-26_012146.